Skip to main content
UniHealth

Doctor search

Aman Chauhan, MD

Hematology/Oncology · Berkeley

NPI 1902193147

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
3
Since medical school
16 years
Graduated 2010

Offices

3 locations · UCSF Medical Group Business Services · University of California San Francisco · University of Miami

Looking this up.

Hospitals listed: Univ of Miami Hospital and Clinics-Sylvester Compr. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chauhan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

State licence records

1 licence

  • Florida ME160009Medical Doctor · since 2022 · expires 2027-01-31
    ActiveNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

School, training and certification

2 placements

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Education

  • Kasturba Medical College Manipal · MD2004–2010Medical school

Residency and fellowship

  • University of Kentucky, Hematology and OncologyLEXINGTON, KY · 2015–2018
  • Louisiana State University, Internal Medicine/PediatricsNEW ORLEANS, LA · 2011–2015

What else the board holds

Also licensed in

States the clinician told their board they are also licensed in. Only the states we check are verified.

Kentucky

Original Medicare doctor bills

$40,592

Medicare paid this office $40,592 for 122 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)77$21,956$125
Return visit (30+ min)55$7,183$84
New patient visit (60+ min)35$5,690$163
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's64$1,954$15
Short return visit (20+ min)13$840$60

Who their Medicare patients are

122 Original Medicare patients in 2024. Average age 71 · Women 55% · Also on Medicaid 23% · Health risk score 3.12. Sicker patients than 9 in 10 peers; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 75% · Cancer 55% · Diabetes 39% · Coronary heart disease 30% · Chronic kidney disease 30% · Depression 28% · COPD 17% · Heart failure 16% · Atrial fibrillation 16% · Stroke 10%.

The office billed $147,492, Medicare allowed $52,053 and paid $40,592; for 468 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024122468713.12$147,492$40,592
202373193692.84$85,308$22,807
202267125692.29$37,665$12,793
202194223702.82$65,860$21,948
202096254702.60$73,536$21,080
2019100220682.36$57,499$16,317
20182448681.61$14,320$4,211

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)39$12,691$122
New patient visit (60+ min)25$3,992$160
Return visit (30+ min)23$2,961$82

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)26$6,137$114
Return visit (30+ min)20$2,045$73
New patient visit (60+ min)11$1,532$139

2021: 5 services

Original Medicare services billed in 2021
Long return visit (40+ min)38$10,973$110
Return visit (30+ min)32$3,431$70
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,465$154
New patient visit (60+ min)14$1,919$137
Short return visit (20+ min)11$785$49

2020: 5 services

Original Medicare services billed in 2020
Long return visit (40+ min)31$8,539$82
Return visit (30+ min)31$3,419$58
Initial hospital care with moderate level of medical decision making at least 75 minutes21$3,352$160
New patient visit (45+ min)12$1,223$102
Short return visit (20+ min)13$566$38

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)29$4,208$59
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes29$3,029$104
Long return visit (40+ min)15$2,626$85
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,698$154
Short return visit (20+ min)14$701$39

Medicaid work

$5,848 in 2021

Medicaid paid $5,848 for 141 billed services this clinician did in 2021, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2021
Long return visit (40+ min)141$5,848
Medicaid work by year
2021141114$5,848
202078114$3,165
See the largest Medicaid services in earlier years

2020

Largest Medicaid services in 2020
Long return visit (40+ min)78$3,165

Drugs they prescribed that Part D paid

$229,844

Pharmacies billed $229,844 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 8% of their Part D prescriptions (13 of 161) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%.

135 generic and 26 brand-name prescriptions · $229,844 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Everolimus26$41,056$1,579
Prochlorperazine Maleate16$303$19
Dexamethasone17$138$8
Methylprednisolone18$102$6

Year by year

Part D prescribing by year
2024161518% (13)16%$229,844
20231643310% (16)15%$298,449
20223073311% (35)30%$380,675
20213564521% (73)None$385,954
20204985026% (131)None$191,532
20191782821% (37)None$93,046
201821NoneNoneNone$528
20174318NoneNone$8,942
201611None0% (0)0%$667
20153915NoneNone$1,134
201414None0% (0)None$382
201313None0% (0)None$1,424

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Everolimus16$174,408$10,900
Xermelo12$109,843$9,154
Prochlorperazine Maleate30$629$21
Ondansetron Odt21$521$25

2022: 13 drugs

Part D drugs prescribed in 2022
Xermelo22$176,436$8,020
Afinitor12$163,564$13,630
Eliquis19$13,082$689
Xarelto16$10,227$639
Dronabinol11$2,668$243
Ondansetron29$759$26
Oxycodone17$609$36
Prochlorperazine Maleate31$412$13
Olanzapine12$170$14
Dexamethasone11$143$13
Sertraline11$128$12
Prednisone14$45$3
Lorazepam12$13$1

2021: 8 drugs

Part D drugs prescribed in 2021
Xermelo26$190,499$7,327
Oxycodone43$1,228$29
Ondansetron31$1,057$34
Prochlorperazine Maleate34$1,018$30
Morphine Sulfate Er24$1,011$42
Dexamethasone20$378$19
Mirtazapine15$129$9
Pantoprazole13$63$5

2020: 10 drugs

Part D drugs prescribed in 2020
Ondansetron56$4,380$78
Dronabinol23$3,332$145
Oxycodone90$2,497$28
Prochlorperazine Maleate46$1,728$38
Morphine Sulfate Er34$1,182$35
Dexamethasone36$521$14
Alprazolam15$167$11
Levothyroxine11$134$12
Promethazine11$128$12
Mirtazapine17$106$6

2019: 5 drugs

Part D drugs prescribed in 2019
Oxycodone24$841$35
Ondansetron21$591$28
Dexamethasone17$514$30
Prochlorperazine Maleate17$438$26
Mirtazapine11$143$13

Money from drug and device companies

$33,351 in 2025

Industry payments by year
2025640$27,769$33,351
2024632$19,690$24,934
202345$14,468$14,489
202233$4,090$4,215
202138$10,508$10,713
202029$7,850$9,124
201937$1,820$2,619

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
ExelixisCabometyx$13,128
24 payments
  • Paid to speak or teach for Cabometyx · 2025-12-18 · $300
  • Paid to speak or teach for Cabometyx · 2025-11-13 · $900
  • Travel for Cabometyx · 2025-11-01 · $187
  • Meals for Cabometyx · 2025-11-01 · $67
  • Meals · 2025-10-23 · $175
  • Meals for Cabometyx · 2025-10-18 · $172
  • Consulting for Cabometyx · 2025-10-09 · $3,300
  • Travel for Cabometyx · 2025-10-06 · $190
  • Travel for Cabometyx · 2025-10-03 · $354
  • Travel for Cabometyx · 2025-10-03 · $824
  • Travel for Cabometyx · 2025-10-03 · $190
  • Travel for Cabometyx · 2025-10-01 · $6
  • Travel for Cabometyx · 2025-09-30 · $70
  • Travel for Cabometyx · 2025-09-30 · $573
  • Travel for Cabometyx · 2025-09-30 · $70
  • Travel for Cabometyx · 2025-09-30 · $47
  • Travel for Cabometyx · 2025-09-30 · $36
  • Meals for Cabometyx · 2025-09-20 · $137
  • Paid to speak or teach for Cabometyx · 2025-07-25 · $900
  • Honoraria for Cabometyx · 2025-07-23 · $2,400
  • Meals for Cabometyx · 2025-05-29 · $144
  • Travel for Cabometyx · 2025-05-28 · $352
  • Travel for Cabometyx · 2025-05-28 · $834
  • Paid to speak or teach for Cabometyx · 2025-03-28 · $900
Boehringer Ingelheim PharmaceuticalsSpevigo$12,021
5 payments
  • Consulting · 2025-12-08 · $6,598
  • Meals · 2025-10-25 · $59
  • Consulting · 2025-08-19 · $1,480
  • Consulting · 2025-05-30 · $925
  • Consulting for Spevigo · 2025-02-18 · $2,960
GenzymeNone$4,143
3 payments
  • Consulting · 2025-01-22 · $3,677
  • Travel · 2025-01-22 · $352
  • Meals · 2025-01-22 · $115
TerSera TherapeuticsXermelo$3,541
3 payments
  • Consulting for Xermelo · 2025-10-22 · $3,430
  • Meals for Xermelo · 2025-10-22 · $50
  • Meals for Xermelo · 2025-10-22 · $61
Novartis PharmaceuticalsNone$312
2 payments
  • Meals · 2025-03-01 · $274
  • Travel · 2025-03-01 · $37
Curium USDetectnet$206
3 payments
  • Meals for Detectnet · 2025-03-02 · $37
  • Meals for Detectnet · 2025-03-02 · $78
  • Meals for Detectnet · 2025-02-11 · $92
See all 40 published payments
Every published payment
ExelixisPaid to speak or teach · 2025-12-18Cabometyx$300
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-12-08None$6,598
ExelixisPaid to speak or teach · 2025-11-13Cabometyx$900
ExelixisTravel · 2025-11-01Cabometyx$187
ExelixisMeals · 2025-11-01Cabometyx$67
Boehringer Ingelheim PharmaceuticalsMeals · 2025-10-25None$59
ExelixisMeals · 2025-10-23None$175
TerSera TherapeuticsConsulting · 2025-10-22Xermelo$3,430
TerSera TherapeuticsMeals · 2025-10-22Xermelo$50
TerSera TherapeuticsMeals · 2025-10-22Xermelo$61
ExelixisMeals · 2025-10-18Cabometyx$172
ExelixisConsulting · 2025-10-09Cabometyx$3,300
ExelixisTravel · 2025-10-06Cabometyx$190
ExelixisTravel · 2025-10-03Cabometyx$354
ExelixisTravel · 2025-10-03Cabometyx$824
ExelixisTravel · 2025-10-03Cabometyx$190
ExelixisTravel · 2025-10-01Cabometyx$6
ExelixisTravel · 2025-09-30Cabometyx$70
ExelixisTravel · 2025-09-30Cabometyx$573
ExelixisTravel · 2025-09-30Cabometyx$70
ExelixisTravel · 2025-09-30Cabometyx$47
ExelixisTravel · 2025-09-30Cabometyx$36
ExelixisMeals · 2025-09-20Cabometyx$137
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-08-19None$1,480
ExelixisPaid to speak or teach · 2025-07-25Cabometyx$900
ExelixisHonoraria · 2025-07-23Cabometyx$2,400
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-05-30None$925
ExelixisMeals · 2025-05-29Cabometyx$144
ExelixisTravel · 2025-05-28Cabometyx$352
ExelixisTravel · 2025-05-28Cabometyx$834
ExelixisPaid to speak or teach · 2025-03-28Cabometyx$900
Curium USMeals · 2025-03-02Detectnet$37
Curium USMeals · 2025-03-02Detectnet$78
Novartis PharmaceuticalsMeals · 2025-03-01None$274
Novartis PharmaceuticalsTravel · 2025-03-01None$37
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-02-18Spevigo$2,960
Curium USMeals · 2025-02-11Detectnet$92
GenzymeConsulting · 2025-01-22None$3,677
GenzymeTravel · 2025-01-22None$352
GenzymeMeals · 2025-01-22None$115
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $24,934

Payments by company in 2024
ExelixisCabometyx$15,634
18 payments
  • Honoraria for Cabometyx · 2024-12-13 · $4,800
  • Travel for Cabometyx · 2024-12-06 · $444
  • Travel for Cabometyx · 2024-12-06 · $29
  • Travel for Cabometyx · 2024-12-06 · $70
  • Travel for Cabometyx · 2024-12-06 · $123
  • Travel for Cabometyx · 2024-12-06 · $195
  • Travel for Cabometyx · 2024-12-06 · $464
  • Travel for Cabometyx · 2024-12-05 · $32
  • Honoraria · 2024-07-18 · $4,800
  • Meals · 2024-07-13 · $115
  • Meals · 2024-07-13 · $65
  • Honoraria for Cabometyx · 2024-05-16 · $3,000
  • Meals for Cabometyx · 2024-04-26 · $105
  • Meals for Cabometyx · 2024-04-26 · $59
  • Travel for Cabometyx · 2024-04-26 · $140
  • Travel for Cabometyx · 2024-04-26 · $713
  • Travel for Cabometyx · 2024-04-26 · $287
  • Travel for Cabometyx · 2024-04-26 · $194
Curium USNone$5,093
7 payments
  • Honoraria · 2024-05-15 · $3,250
  • Travel · 2024-05-05 · $246
  • Travel · 2024-05-05 · $385
  • Meals · 2024-05-05 · $146
  • Travel · 2024-05-04 · $456
  • Travel · 2024-05-04 · $335
  • Travel · 2024-05-04 · $275
Lantheus Medical ImagingNone$2,880
2 payments
  • Paid to speak or teach · 2024-07-09 · $2,835
  • Meals · 2024-06-18 · $45
TerSera TherapeuticsXermelo$1,005
2 payments
  • Consulting for Xermelo · 2024-08-07 · $503
  • Consulting for Xermelo · 2024-03-11 · $503
Novartis PharmaceuticalsLutathera$224
2 payments
  • Meals for Lutathera · 2024-04-05 · $117
  • Meals for Leqvio · 2024-02-02 · $107
Ipsen BiopharmaceuticalsOnivyde$98
1 payment
  • Meals for Onivyde · 2024-06-25 · $98

2023: $14,489

Payments by company in 2023
Curium USDetectnet$6,600
2 payments
  • Consulting for Detectnet · 2023-10-05 · $1,800
  • Consulting for Detectnet · 2023-08-24 · $4,800
Novartis PharmaceuticalsLutathera$4,388
1 payment
  • Consulting for Lutathera · 2023-08-14 · $4,388
Ipsen BiopharmaceuticalsSomatuline Depot$3,480
1 payment
  • Consulting for Somatuline Depot · 2023-01-13 · $3,480
Cardinal Health 414None$22
1 payment
  • Meals · 2023-08-25 · $22

2022: $4,215

Payments by company in 2022
Advanced Accelerator ApplicationsLutathera$2,500
1 payment
  • Consulting for Lutathera · 2022-03-25 · $2,500
Jazz PharmaceuticalsZepzelca$1,590
1 payment
  • Consulting for Zepzelca · 2022-12-19 · $1,590
Novartis PharmaceuticalsLutathera$125
1 payment
  • Meals for Lutathera · 2022-01-20 · $125

2021: $10,713

Payments by company in 2021
TerSera TherapeuticsXermelo$7,020
3 payments
  • Consulting for Xermelo · 2021-12-15 · $1,404
  • Consulting for Xermelo · 2021-11-04 · $1,404
  • Consulting for Xermelo · 2021-09-15 · $4,212
Ipsen BiopharmaceuticalsSomatuline Depot$3,604
3 payments
  • Consulting for Somatuline Depot · 2021-12-21 · $1,938
  • Consulting for Somatuline Depot · 2021-12-07 · $1,550
  • Meals for Somatuline Depot · 2021-06-07 · $117
Novartis PharmaceuticalsLutathera$89
2 payments
  • Meals for Lutathera · 2021-09-14 · $48
  • Meals for Lutathera · 2021-07-09 · $40

2020: $9,124

Payments by company in 2020
Lexicon PharmaceuticalsXermelo$7,574
8 payments
  • Consulting for Xermelo · 2020-03-11 · $6,300
  • Meals for Xermelo · 2020-02-21 · $33
  • Meals for Xermelo · 2020-02-21 · $36
  • Meals for Xermelo · 2020-02-21 · $48
  • Travel for Xermelo · 2020-02-20 · $249
  • Meals for Xermelo · 2020-02-20 · $55
  • Travel for Xermelo · 2020-02-14 · $827
  • Meals for Xermelo · 2020-01-23 · $26
Ipsen BiopharmaceuticalsSomatuline Depot$1,550
1 payment
  • Consulting for Somatuline Depot · 2020-06-11 · $1,550

2019: $2,619

Payments by company in 2019
Ipsen BiopharmaceuticalsSomatuline Depot$2,122
4 payments
  • Meals for Somatuline Depot · 2019-10-04 · $137
  • Consulting for Somatuline Depot · 2019-10-03 · $1,820
  • Meals for Somatuline Depot · 2019-10-03 · $88
  • Meals for Somatuline Depot · 2019-04-19 · $77
Ipsen InnovationSomatuline Depot$474
2 payments
  • Travel for Somatuline Depot · 2019-07-15 · $421
  • Travel for Somatuline Depot · 2019-07-15 · $53
ExelixisNone$22
1 payment
  • Meals · 2019-04-01 · $22

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-9: A Phase Ib Open-Label Dose Escalation and Dose Confirmation Safety Study of Intravenous Bi 764532 in Combination With A Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-Based Chemotherapy · 2025Their institution$1,207,047
Alkermes, Inc. · A Study of the Effects of Alks 4230 on Subjects With Solid Tumors · 2020Their institution$763,784
Novartis Pharmaceuticals Corporation · Net Retreat: A Phase II Rct of Lu-177 Dotatate Retreatment Vs. Everolimus in Metastatic/Unresectable Small Bowel Net · 2025Their institution$726,648
Novartis Pharmaceuticals Corporation · Net Retreat: A Phase II Rct of Lu-177 Dotatate Retreatment Vs. Everolimus in Metastatic/Unresectable Small Bowel Net · 2024Their institution$438,400
Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial To Investigate Safety and Tolerability of Bi 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patients With Neuroendocrine Carcinomas (Nec) · 2025Their institution$415,685
Boehringer Ingelheim Pharmaceuticals, Inc. · Phase II Study in Sclc and Epnec · 2024Their institution$412,272
Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2021Their institution$284,900
Boehringer Ingelheim Pharmaceuticals, Inc. · Phi in 2l Sclc With Combination of Bi 764532 + Topotecan · 2024Their institution$254,648
Boehringer Ingelheim Pharmaceuticals, Inc. · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025Their institution$134,240
Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2022Their institution$68,000
TerSera Therapeutics LLC · Telotristate With Lutathera in Nets · 2020Their institution$50,484
Amgen Inc. · Tarlatamab 20200439 · 2023Their institution$41,817
Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2020Their institution$34,000
Clovis Oncology, Inc. · Phase II Study of Combination Rucaparib With Nivolumab in Platinum Sensitive Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet · 2019Their institution$25,000
E.R. Squibb & Sons, L.L.C. · Phase 1b/3 Global, Randomized, Controlled, Open-Label Trial Comparing Treatment With Ryz101 To Standard of Care Therapy in Subjects With Inoperable, Advanced, Sstr+, Well-Differentiated Gep-Nets That Have Progressed Following Prior 177lu-Ssa Therapy · 2024Their institution$23,944
Novartis Pharmaceuticals Corporation · Lumiere: A Phase 1/2, Multicenter, Open-Label, Non-Randomized Study To Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177lu-Fap-2286 in Patients With An Advanced Solid Tumor · 2025Their institution$23,654
Boehringer Ingelheim Pharmaceuticals, Inc. · Phi in Dll3+ 1l Epnec With Bi 764532 + Chemo · 2024Their institution$22,914
E.R. Squibb & Sons, L.L.C. · Phase 1b Single Arm, Open-Label Trial of Ryz101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor · 2024Their institution$22,439
E.R. Squibb & Sons, L.L.C. · Phase II Study of Combination Nivolumab With Rucaparib in Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet. · 2023Their institution$20,981
Y-mAbs Therapeutics, Inc. · Phase 1 Trial With Gd2-Sada:177lu-Dota Drug Complex in Patients With Recurrent Or Refractory Metastatic Solid Tumors Known To Express Gd2, Including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma · 2024Their institution$19,670
Novartis Pharmaceuticals Corporation · A Phase Ib Dose Finding Study Assessing Safety and Activity of [177lu]Lu-Dota-Tate in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte · 2022Their institution$14,154
E.R. Squibb & Sons, L.L.C. · Phase II Study of Combination Nivolumab With Rucaparib in Small Cell Lung Carcinoma Patients As Maintenance After Induction Therapy With Platinum Doublet. · 2024Their institution$10,508
Novartis Pharmaceuticals Corporation · Research Publication/Writing Support · 2025This clinician$7,435
NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022This clinician$6,324
Amgen Inc. · Tarlatamab 20200439 · 2021Their institution$6,200
Amgen Inc. · Tarlatamab 20200439 · 2022Their institution$5,856
Boehringer Ingelheim Pharma GmbH & Co.KG · Phase II Study in Sclc and Epnec · 2024Their institution$4,349
Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial To Investigate Safety and Tolerability of Bi 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patients With Neuroendocrine Carcinomas (Nec) · 2025Their institution$3,683
TerSera Therapeutics LLC · Randomized, Parallel Arm, Phase II Study of Telotristat (Xermelo) in Combination With Lutetium Lu 177 Dotatate (Lutathera) in Well Differentiated Neuroendocrine Tumors (Nets) · 2022Their institution$3,558
Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2022Their institution$2,941
Alkermes, Inc. · A Phase 1/2 Study of Alks 4230 Administered Intravenously As Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - Artistry-1 · 2023Their institution$2,694
Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-9: A Phase Ib Open-Label Dose Escalation and Dose Confirmation Safety Study of Intravenous Bi 764532 in Combination With A Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-Based Chemotherapy · 2025Their institution$2,622
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025This clinician$2,442
Boehringer Ingelheim Pharma GmbH & Co.KG · Phi in 2l Sclc With Combination of Bi 764532 + Topotecan · 2024Their institution$1,622
Boehringer Ingelheim Pharma GmbH & Co.KG · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025Their institution$1,484
Boehringer Ingelheim International GmbH · Phase II Study in Sclc and Epnec · 2024Their institution$785
Boehringer Ingelheim International GmbH · Dareon-5: An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous Bi 764532, A Dll3-Targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas · 2025Their institution$640
Novartis Pharmaceuticals Corporation · A Multicenter Open-Label Study To Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (Gep-Net) Tumors, Pheochromocytoma and Paragangliomas · 2023Their institution$421
Boehringer Ingelheim Pharma GmbH & Co.KG · Phi in Dll3+ 1l Epnec With Bi 764532 + Chemo · 2024Their institution$370
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177lu]Lu-Ff58 in Patients With Selected Advanced Solid Tumors · 2024Their institution$284
Novartis Pharmaceuticals Corporation · A Phase Ib Dose Finding Study Assessing Safety and Activity of [177lu]Lu-Dota-Tate in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (Es-Sclc) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte · 2025Their institution$158
Novartis Pharmaceuticals Corporation · A Phase III Multi-Center, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced Gep-Net · 2023Their institution$140
Novartis Pharmaceuticals Corporation · A Multicenter Open-Label Study To Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (Gep-Net) Tumors, Pheochromocytoma and Paragangliomas · 2024Their institution$102

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1902193147
Licence
FL ME160009Florida ME160009: Active
Group
UCSF Medical Group Business Services · University of California San Francisco · University of Miami
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
1120 Nw 14th St Fl 6, Miami, FL, 33136
NPI first listed
2011-07-08
NPI last updated
2025-12-04
NPI record certified
2025-12-04

This is when the NPI record was last certified, not a medical board exam.